United States set
language
Menu Shopping cart $0 Search
Manufactured by BioVendor

Human Visfatin (NAMPT) ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, HRP-labelled antibody
  • Other names:NAMPT, Pre-B cell colony-enhancing factor, PBEF, Nicotinamide phosphoribosyltransferase, NAmPRTase, EC=2.4.2.12, Pre-B-cell colony-enhancing factor 1, PBEF1, NAMPT
  • Species:Human
Cat. No. Size Price


RAG004R 96 wells (1 kit) $682
PubMed Product Details
Technical Data

Type

Sandwich ELISA, HRP-labelled antibody

Description

The Human (Nampt/PBEF) ELISA Kit is to be used for the in vitro quantitative determination of human Visfatin in serum and plasma. This ELISA Kit is for research use only.

Applications

Serum, Plasma

Sample Requirements

100 μl/well

Shipping

On blue ice packs. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.125 - 8 ng/ml

Limit of Detection

30 pg/ml

Spiking Recovery

98%

Dilution Linearity

85-105%

Physical Appearance

White lyophilized (freeze-dried) powder.

Specificity

This ELISA is specific for the measurement of natural and recombinant human Nampt. It does not cross-react with human adiponectin, human resistin, human vaspin, human RBP4, human GPX3, human progranulin, human IL-33, human clusterin, human ANGPTL3, human ANGPTL4, human ANGPTL6, mouse RBP4.

Note

More about Visfatin on BioVendor Scientific Blog

Summary

Features

  • RUO
  • calibration range 0.125-8 ng/ml
  • limit of detection 30 pg/ml

Research topic

Cytokines and chemokines and related molecules, Energy metabolism and body weight regulation

Summary

Fukuhara et al. (1) isolated visfatin, an adipocytokine that is highly enriched in the visceral fat of both humans and mice and whose expression level in plasma increases during the development of obesity. Visfatin corresponds to pre-B cell colony-enhancing factor (PBEF), a 52-kD cytokine expressed in lymphocytes. The gene encoding PBEF was originally isolated from an activated lymphocyte cDNA library (2). Although PBEF lacks a typical signal sequence for secretion, transfected COS-7 and mouse embryonic fibroblasts secreted PBEF into the culture medium. Samal et al. (2) found that recombinant PBEF secreted from transfected COS-7 and mouse embryonic fibroblasts was not itself active in a pre-B-cell colony formation assay, but it synergized the pre-B-cell colony formation activity of stem cell factor and interleukin-7. Jia et al. (3) found that PBEF is an inflammatory cytokine that plays a requisite role in the delayed neutrophil apoptosis of sepsis. Visfatin exerted insulin-mimetic effects in cultured cells and lowered plasma glucose levels in mice. Mice heterozygous for a targeted mutation in the visfatin gene had modestly higher levels of plasma glucose relative to wild type littermates. Surprisingly, it was found that visfatin binds to and activates the insulin receptor (1). However, this original discovery has not been reproduced by two groups (4-5). Visfatin, which is a secretory form of Nampt (nicotinamide phosphoribosyl-transferase), the rate-limiting enzyme of the mammalian NAD, plays a key role in secretion of insulin in the pancreatic beta-cells (5). Recently, two recent studies showed that plasma or serum levels of visfatin in patients with type 2 diabetes mellitus was elevated (6-7), suggesting that measurement of plasma visfatin provides a relevant tool for understanding metabolic diseases.

Product References (2)

References

  • Sahpolat M, Ari M, Kokacya MH. Plasma Apelin, Visfatin and Resistin Levels in Patients with First Episode Psychosis and Chronic Schizophrenia. Clin Psychopharmacol Neurosci. 2020 Feb 29;18(1):109-115. doi: 10.9758/cpn.2020.18.1.109. PubMed PMID: 31958911. PubMed CentralPMCID: PMC7006973. See more on PubMed
  • Beck ML, Freihaut B, Henry R, Pierce S, Bayer WL. A serum haemagglutinating property dependent upon polycarboxyl groups. Br J Haematol. 1975 Jan;29(1):149-56. doi: 10.1111/j.1365-2141.1975.tb01808.x. PubMed PMID: 32. See more on PubMed
Summary References (11)

References to Visfatin

  • Arner P. Visfatin--a true or false trail to type 2 diabetes mellitus. J Clin Endocrinol Metab. 2006 Jan;91 (1):28-30
  • Beltowski J. Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity?. Med Sci Monit. 2006 Jun;12 (6):RA112-9
  • Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, Stumvoll M, Bluher M. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes. 2005 Oct;54 (10):2911-6
  • Bottcher Y, Teupser D, Enigk B, Berndt J, Kloting N, Schon MR, Thiery J, Bluher M, Stumvoll M, Kovacs P. Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans. J Clin Endocrinol Metab. 2006 Jul;91 (7):2725-31
  • Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2006 Jan;91 (1):295-9
  • Curat CA, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R, Bouloumie A. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia. 2006 Apr;49 (4):744-7
  • Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005 Jan 21;307 (5708):426-30
  • Haider DG, Mittermayer F, Schaller G, Artwohl M, Baumgartner-Parzer SM, Prager G, Roden M, Wolzt M. Free fatty acids normalize a rosiglitazone-induced visfatin release. Am J Physiol Endocrinol Metab. 2006 Nov;291 (5):E885-90
  • Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab. 2006 Apr;91 (4):1578-81
  • Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, Milan G, Rossato M, Federspil G, Vettor R. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab. 2006 Aug;91 (8):3165-70
  • Pfutzner A, Forst T. Comment on: Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M (2006) the release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 49:1909-1914. Diabetologia. 2006 Nov;49 (11):2795; author reply 2796
Related Products Docs
Subscribe to Our Newsletter! Discover News from
BioVendor R&D
Subscribe Now
Subscribe to Our Newsletter! Discover News from
BioVendor R&D
Subscribe Now
zavřít